| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Useful For Video Overview Clinical Information Several PSA isoforms have been identified that can further increase the specificity of PSA for prostate cancer.[...]
Some early-stage cancers are missed by conventional screening and are only detected when symptoms occur. Mayo Clinic is collaborating with Grail, a life science company, and Sutter Health of California, on the STRIVE clinical research study to facilitate the development of Grail’s blood tests for early-stage cancer detection.
This week’s Research Roundup highlights the best tumor size cut-points for renal cell carcinoma staging.
This week’s Research Roundup highlights how AKT-phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction.